Rucaparib

Manufactured by Merck Group

Sourced in United States

Rucaparib is a laboratory equipment product manufactured by Merck Group. It is a small-molecule inhibitor designed for research and development purposes.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Rucaparib camsylate (4 citations)

5 protocols using rucaparib

Synthesis and Purification of ß-Lap

Check if the same lab product or an alternative is used in the 5 most similar protocols

ß-Lap was synthesized and purified by us and stock solutions prepared at 50 mM in DMSO. Methoxyamine, dicoumarol, Rucaparib and BAPTA-AM were purchased from Sigma-Aldrich (St. Louis, MO).

Chakrabarti G., Silvers M.A., Ilcheva M., Liu Y., Moore Z.R., Luo X., Gao J., Anderson G., Liu L., Sarode V., Gerber D.E., Burma S., DeBerardinis R.J., Gerson S.L, & Boothman D.A. (2015). Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Scientific Reports, 5, 17066.

+ Open protocol

+ Expand

Comparing PARP-1 Inhibitor Efficacy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Different doses of new non-NAD-like PARP-1 inhibitors or classical PARP-1 inhibitors Olaparib (Astra Zeneca, USA), Veliparib (ALX-270–444, Enzo, USA) and Rucaparib (PZ0036, Sigma-Aldrich, USA) were added to the cells cultured in complete medium. After 24 or 48 h, cells were lysed, and protein samples were analyzed with SDS-PAGE and Western Blot using anti-pADPr antibody (1:500, mouse, 1020, Tulip Biolabs, USA).

Karpova Y., Wu C., Divan A., McDonnell M.E., Hewlett E., Makhov P., Gordon J., Ye M., Reitz A., Childers W.E., Skorski T., Kolenko V, & Tulin A.V. (2019). Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical pharmacology, 167, 149-162.

+ Open protocol

+ Expand

In vivo Lung Metastasis Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the in vivo drug treatment studies, 5 × 10⁵ MDA-Par cells were injected via tail vein. Mice were then injected intraperitoneally with rucaparib (15 mg kg⁻¹, Sigma-Aldrich) or retro-orbitally with saline control and β-lapachone (22 mg kg⁻¹, Sigma-Aldrich) or HPβCD vehicle (600 mg kg⁻¹, Sigma-Aldrich). IKE (23 mg kg⁻¹, catalog no. 27088, Cayman Chemical) or saline control was injected intraperitoneally in the appropriate cohorts. β-lapachone, rucaparib and IKE injections were repeated daily for 5 d. Lungs were extracted at the endpoint and stained with H&E.

Culbertson B., Garcia K., Markett D., Asgharian H., Chen L., Fish L., Navickas A., Yu J., Woo B., Nanda A.S., Choi B., Zhou S., Rabinowitz J, & Goodarzi H. (2023). A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression. Nature Cancer, 4(5), 682-698.

+ Open protocol

+ Expand

Preparation and Storage of PARP Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Olaparib (#S1060) and rucaparib (#S1098) were purchased from Selleck Chemicals, Houston, TX. Hydroxyurea (HU; #H8627) was from Sigma-Aldrich. ADH-1 (N-cadherin inhibitor; #HY-13541) and prexasertib (CHK1 inhibitor; #HY-18174) were from MedChemExpress (Monmouth Junction, NJ). 100 mM of Olaparib, 10 mM of rucaparib, HU, ADH-1, and prexasertib were prepared as stocks in dimethyl sulfoxide (DMSO; #S-002-M, Sigma-Aldrich, Saint Louis, MO). All drugs were stored in aliquots at −80 °C until use.

Huang T.T., Burkett S.S., Tandon M., Yamamoto T.M., Gupta N., Bitler B.G., Lee J.M, & Nair J.R. (2022). Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. Oncogene, 41(46), 5020-5031.

+ Open protocol

+ Expand

Assessing Cellular Effects of Chemotherapeutics

Check if the same lab product or an alternative is used in the 5 most similar protocols

Carboplatin, oxaliplatin, cisplatin, rucaparib, Trolox, and MitoTempo were from Sigma-Aldrich (St. Louis, MO, USA). All other materials for cellular experiments were from Sigma-Aldrich, unless otherwise stated.

Kacsir I., Sipos A., Ujlaki G., Buglyó P., Somsák L., Bai P, & Bokor É. (2021). Ruthenium Half-Sandwich Type Complexes with Bidentate Monosaccharide Ligands Show Antineoplastic Activity in Ovarian Cancer Cell Models through Reactive Oxygen Species Production. International Journal of Molecular Sciences, 22(19), 10454.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!